Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y
No placebo
The Lp(a) HORIZON phase 3 CVOT (topline anticipated in the first half of 2026) targets cardiovascular risk in patients with established CVD and elevated Lp(a)
Certificate of Analysis lot-specific COA ships with every order and is available on request
It is currently in Phase 3 clinical trials, and regulatory approval is expected to be sought once those trials concludepossibly by late 2025 or early 2026
Mislabeled Vials: The majority of products tested were found to be completely mislabeled, containing a different substance entirely or no active ingredient at all
US$ 20.32
US$ 23.11
US$ 24.83
US$ 28.24
